<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35257468</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1463-1326</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes, obesity &amp; metabolism</Title>
          <ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Feasibility study of a prototype extended-wear insulin infusion set in adults with type 1 diabetes.</ArticleTitle>
        <Pagination>
          <StartPage>1143</StartPage>
          <EndPage>1149</EndPage>
          <MedlinePgn>1143-1149</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.14685</ELocationID>
        <Abstract>
          <AbstractText Label="AIM">To assess the feasibility of a prototype insulin infusion set (IIS) for extended wear in adults with type 1 diabetes.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS">The prototype Capillary Biomedical investigational extended-wear IIS (CBX IIS) incorporates a soft, flexible, reinforced kink-resistant angled nylon-derivative cannula with one distal and three proximal ports to optimize insulin delivery. Twenty adult participants with type 1 diabetes established on insulin pump therapy used the CBX IIS for two 7-day test periods while wearing a Dexcom G5 continuous glucose monitor.</AbstractText>
          <AbstractText Label="RESULTS">Participants were able to wear the CBX IIS for an average of 6.6 ± 1.4 days. Eighty-eight percent (36 of 41) of sets were worn for 7 days. No serious adverse events were reported. Five infusion sets failed prematurely because of: unresolvable hyperglycaemia (three); hyperglycaemia with elevated ketones (one); or infection (one). Median time in range (3.9-10.0 mmol/L) was 62% (54-76). Average glucose levels per day of infusion set wear showed a statistically significant increase over time (p &lt; .001).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Our preliminary observations confirm the tolerability of the prototype CBX IIS for extended wear, albeit with a deterioration in glucose control after the third day.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kastner</LastName>
            <ForeName>Jasmin R</ForeName>
            <Initials>JR</Initials>
            <Identifier Source="ORCID">0000-0002-0821-3778</Identifier>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Artificial Pancreas Center, Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venkatesh</LastName>
            <ForeName>Nisha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Katie</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muchmore</LastName>
            <ForeName>Douglas B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ekinci</LastName>
            <ForeName>Elif</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-2372-395X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, Austin Health, Heidelberg, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Melbourne Medical School, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fourlanos</LastName>
            <ForeName>Spiros</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joseph</LastName>
            <ForeName>Jeffrey I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Artificial Pancreas Center, Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shafeeq</LastName>
            <ForeName>Miami</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Leon</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Integrated Medical Development, LLC, Princeton Junction, New Jersey, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strange</LastName>
            <ForeName>Poul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Integrated Medical Development, LLC, Princeton Junction, New Jersey, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strasma</LastName>
            <ForeName>Paul J</ForeName>
            <Initials>PJ</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Neal</LastName>
            <ForeName>David N</ForeName>
            <Initials>DN</Initials>
            <Identifier Source="ORCID">0000-0002-0870-4032</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Diabetes Obes Metab</MedlineTA>
        <NlmUniqueID>100883645</NlmUniqueID>
        <ISSNLinking>1462-8902</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006943" MajorTopicYN="Y">Hyperglycemia</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007332" MajorTopicYN="N">Insulin Infusion Systems</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CSII</Keyword>
        <Keyword MajorTopicYN="Y">insulin pump therapy</Keyword>
        <Keyword MajorTopicYN="Y">phase I-II study</Keyword>
        <Keyword MajorTopicYN="Y">type 1 diabetes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35257468</ArticleId>
        <ArticleId IdType="doi">10.1111/dom.14685</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Heinemann L. Insulin infusion sets: a critical reappraisal. Diabetes Technol Ther. 2016;18:327-333.</Citation>
        </Reference>
        <Reference>
          <Citation>Hauzenberger JR, Hipszer BR, Loeum C, et al. Detailed analysis of insulin absorption variability and the tissue response to continuous subcutaneous insulin infusion catheter implantation in swine. Diabetes Technol Ther. 2017;19:641-650.</Citation>
        </Reference>
        <Reference>
          <Citation>Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4:673-682.</Citation>
        </Reference>
        <Reference>
          <Citation>Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al. Factors affecting the absorption of subcutaneously administered insulin: effect on variability. J Diabetes Res. 2018;2018:1-17.</Citation>
        </Reference>
        <Reference>
          <Citation>Nwadiugwu MC, Bastola DR, Haas C, Russell D. Identifying glycemic variability in diabetes patient cohorts and evaluating disease outcomes. J Clin Med. 2021;10:1477.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmid V, Hohberg C, Borchert M, Forst T, Pfützner A. Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3. J Diabetes Sci Technol. 2010;4:976-982.</Citation>
        </Reference>
        <Reference>
          <Citation>Swan KL, Dziura JD, Steil GM, et al. Effect of age of infusion site and type of rapid-acting analog on Pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009;32:240-244.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel PJ, Benasi K, Ferrari G, et al. Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther. 2014;16:15-19.</Citation>
        </Reference>
        <Reference>
          <Citation>Pfützner A, Sachsenheimer D, Grenningloh M, et al. Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events: results from a prospective randomized crossover study. J Diabetes Sci Technol. 2015;9:1292-1298. doi:10.1177/1932296815604438</Citation>
        </Reference>
        <Reference>
          <Citation>Waldenmaier D, Zschornack E, Buhr A, Pleus S, Haug C, Freckmann G. A prospective study of insulin infusion set use for up to 7 days: early replacement reasons and impact on glycemic control. Diabetes Technol Ther. 2020;22:734-741. doi:10.1089/dia.2019.0445</Citation>
        </Reference>
        <Reference>
          <Citation>Lal RA, Hsu L, Zhang J, Schøndorff PK, Heschel M, Buckingham B. Longevity of the novel ConvaTec infusion set with lantern technology. Diabetes Obes Metab. 2021;23:1973-1977. doi:10.1111/dom.14395</Citation>
        </Reference>
        <Reference>
          <Citation>Simic A, Schøndorff PK, Stumpe T, et al. Survival assessment of the extended-wear insulin infusion set featuring lantern technology in adults with type 1 diabetes by the glucose clamp technique. Diabetes Obes Metab. 2021;23:1402-1408.</Citation>
        </Reference>
        <Reference>
          <Citation>Ilany J, Cohen O, Konvalina N, Zhang G &amp; Chattaraj S Clinical Study of a New Extended Wear Infusion Set Design. Presented at Advanced Technologies &amp; Treatments for Diabetes Conference, 19-22 February, 2020, Madrid, Spain (2020). Diabetes Technology &amp; Therapeutics.Feb 2020.A-1-A-250. https://doi.org/10.1089/dia.2020.2525.abstracts</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang JY, Shang T, Chattaraj S, et al. Advances in insulin pump infusion sets symposium report. J Diabetes Sci Technol. 2021;15:705-709.</Citation>
        </Reference>
        <Reference>
          <Citation>Buckingham, B. A., Brazg, R. L., Bailey, T. S., Kudva, Y. C., Garg, S. K., Grunberger, G., Thrasher, J., Cavale, A., Bhargaba, A., Horowitz, B., Kaiserman, K., Huang, S., Chen, V., Zhang, G., Chattaraj, S., Shin, J. &amp; Vigersky, R. 100-LB - infusion set survival and performance during the Medtronic extended-wear infusion set (EWIS) pivotal trial. Presented at: American Diabetes Association Virtual 81st Scientific Sessions; June 25-29, 2021; online (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Kastner, J. R., Eisler, G., Torjman, M. C., Khalf, A., Diaz, D., Dinesen, A. R., Loeum, C., Thakur, M. L., Strasma, P. &amp; Joseph, J. I. Novel kink-resistant insulin infusion set causes significantly less subcutaneous tissue inflammation compared with a straight Teflon insulin infusion set. Presented at Advanced Technologies &amp; Treatments for Diabetes Conference, 19-22 February, 2020, Madrid, Spain (2020). Diabetes Technology &amp; Therapeutics.Feb 2020.A-1-A-250. https://doi.org/10.1089/dia.2020.2525.abstracts</Citation>
        </Reference>
        <Reference>
          <Citation>Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593-1603.</Citation>
        </Reference>
        <Reference>
          <Citation>Gomez-Peralta F, Dunn T, Landuyt K, Xu Y, Merino-Torres JF. Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. BMJ Open Diabetes Res Care. 2020;8:e001052.</Citation>
        </Reference>
        <Reference>
          <Citation>Šoupal J, Petruželková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care. 2020;43:37-43.</Citation>
        </Reference>
        <Reference>
          <Citation>Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23:601-608.</Citation>
        </Reference>
        <Reference>
          <Citation>Kesserwan S, Mulka A, Sharafieh R, et al. Advancing continuous subcutaneous insulin infusion in vivo: new insights into tissue challenges. J Biomed Mater Res A. 2020;109:1065-1079. doi:10.1002/jbm.a.37097</Citation>
        </Reference>
        <Reference>
          <Citation>Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152:622-628.</Citation>
        </Reference>
        <Reference>
          <Citation>Pickup JC, Yemane N, Brackenridge A, Pender S. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther. 2014;16:145-149.</Citation>
        </Reference>
        <Reference>
          <Citation>van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin Glulisine compared to insulin Aspart and to insulin Lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13:607-614.</Citation>
        </Reference>
        <Reference>
          <Citation>Kovatchev B. Glycemic variability: risk factors, assessment, and control. J Diabetes Sci Technol. 2019;13:627-635. doi:10.1177/1932296819826111</Citation>
        </Reference>
        <Reference>
          <Citation>Pfützner A, Musholt PB, Malmgren-Hansen B, Nilsson NH, Forst T. Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste. J Diabetes Sci Technol. 2011;5:843-847.</Citation>
        </Reference>
        <Reference>
          <Citation>Heinemann L, Krisiunas E. Diabetes technology and waste: a complex problem piling up! J Diabetes Sci Technol. 2019;13:815-816.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35257468</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1463-1326</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes, obesity &amp; metabolism</Title>
          <ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Feasibility study of a prototype extended-wear insulin infusion set in adults with type 1 diabetes.</ArticleTitle>
        <Pagination>
          <StartPage>1143</StartPage>
          <EndPage>1149</EndPage>
          <MedlinePgn>1143-1149</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.14685</ELocationID>
        <Abstract>
          <AbstractText Label="AIM">To assess the feasibility of a prototype insulin infusion set (IIS) for extended wear in adults with type 1 diabetes.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS">The prototype Capillary Biomedical investigational extended-wear IIS (CBX IIS) incorporates a soft, flexible, reinforced kink-resistant angled nylon-derivative cannula with one distal and three proximal ports to optimize insulin delivery. Twenty adult participants with type 1 diabetes established on insulin pump therapy used the CBX IIS for two 7-day test periods while wearing a Dexcom G5 continuous glucose monitor.</AbstractText>
          <AbstractText Label="RESULTS">Participants were able to wear the CBX IIS for an average of 6.6 ± 1.4 days. Eighty-eight percent (36 of 41) of sets were worn for 7 days. No serious adverse events were reported. Five infusion sets failed prematurely because of: unresolvable hyperglycaemia (three); hyperglycaemia with elevated ketones (one); or infection (one). Median time in range (3.9-10.0 mmol/L) was 62% (54-76). Average glucose levels per day of infusion set wear showed a statistically significant increase over time (p &lt; .001).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Our preliminary observations confirm the tolerability of the prototype CBX IIS for extended wear, albeit with a deterioration in glucose control after the third day.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kastner</LastName>
            <ForeName>Jasmin R</ForeName>
            <Initials>JR</Initials>
            <Identifier Source="ORCID">0000-0002-0821-3778</Identifier>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Artificial Pancreas Center, Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venkatesh</LastName>
            <ForeName>Nisha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Katie</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muchmore</LastName>
            <ForeName>Douglas B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ekinci</LastName>
            <ForeName>Elif</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-2372-395X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, Austin Health, Heidelberg, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Melbourne Medical School, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fourlanos</LastName>
            <ForeName>Spiros</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joseph</LastName>
            <ForeName>Jeffrey I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Artificial Pancreas Center, Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shafeeq</LastName>
            <ForeName>Miami</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Leon</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Integrated Medical Development, LLC, Princeton Junction, New Jersey, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strange</LastName>
            <ForeName>Poul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Integrated Medical Development, LLC, Princeton Junction, New Jersey, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strasma</LastName>
            <ForeName>Paul J</ForeName>
            <Initials>PJ</Initials>
            <AffiliationInfo>
              <Affiliation>Capillary Biomedical Inc., Irvine, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Neal</LastName>
            <ForeName>David N</ForeName>
            <Initials>DN</Initials>
            <Identifier Source="ORCID">0000-0002-0870-4032</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Diabetes Obes Metab</MedlineTA>
        <NlmUniqueID>100883645</NlmUniqueID>
        <ISSNLinking>1462-8902</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006943" MajorTopicYN="Y">Hyperglycemia</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007332" MajorTopicYN="N">Insulin Infusion Systems</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CSII</Keyword>
        <Keyword MajorTopicYN="Y">insulin pump therapy</Keyword>
        <Keyword MajorTopicYN="Y">phase I-II study</Keyword>
        <Keyword MajorTopicYN="Y">type 1 diabetes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35257468</ArticleId>
        <ArticleId IdType="doi">10.1111/dom.14685</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Heinemann L. Insulin infusion sets: a critical reappraisal. Diabetes Technol Ther. 2016;18:327-333.</Citation>
        </Reference>
        <Reference>
          <Citation>Hauzenberger JR, Hipszer BR, Loeum C, et al. Detailed analysis of insulin absorption variability and the tissue response to continuous subcutaneous insulin infusion catheter implantation in swine. Diabetes Technol Ther. 2017;19:641-650.</Citation>
        </Reference>
        <Reference>
          <Citation>Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4:673-682.</Citation>
        </Reference>
        <Reference>
          <Citation>Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al. Factors affecting the absorption of subcutaneously administered insulin: effect on variability. J Diabetes Res. 2018;2018:1-17.</Citation>
        </Reference>
        <Reference>
          <Citation>Nwadiugwu MC, Bastola DR, Haas C, Russell D. Identifying glycemic variability in diabetes patient cohorts and evaluating disease outcomes. J Clin Med. 2021;10:1477.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmid V, Hohberg C, Borchert M, Forst T, Pfützner A. Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3. J Diabetes Sci Technol. 2010;4:976-982.</Citation>
        </Reference>
        <Reference>
          <Citation>Swan KL, Dziura JD, Steil GM, et al. Effect of age of infusion site and type of rapid-acting analog on Pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009;32:240-244.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel PJ, Benasi K, Ferrari G, et al. Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther. 2014;16:15-19.</Citation>
        </Reference>
        <Reference>
          <Citation>Pfützner A, Sachsenheimer D, Grenningloh M, et al. Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events: results from a prospective randomized crossover study. J Diabetes Sci Technol. 2015;9:1292-1298. doi:10.1177/1932296815604438</Citation>
        </Reference>
        <Reference>
          <Citation>Waldenmaier D, Zschornack E, Buhr A, Pleus S, Haug C, Freckmann G. A prospective study of insulin infusion set use for up to 7 days: early replacement reasons and impact on glycemic control. Diabetes Technol Ther. 2020;22:734-741. doi:10.1089/dia.2019.0445</Citation>
        </Reference>
        <Reference>
          <Citation>Lal RA, Hsu L, Zhang J, Schøndorff PK, Heschel M, Buckingham B. Longevity of the novel ConvaTec infusion set with lantern technology. Diabetes Obes Metab. 2021;23:1973-1977. doi:10.1111/dom.14395</Citation>
        </Reference>
        <Reference>
          <Citation>Simic A, Schøndorff PK, Stumpe T, et al. Survival assessment of the extended-wear insulin infusion set featuring lantern technology in adults with type 1 diabetes by the glucose clamp technique. Diabetes Obes Metab. 2021;23:1402-1408.</Citation>
        </Reference>
        <Reference>
          <Citation>Ilany J, Cohen O, Konvalina N, Zhang G &amp; Chattaraj S Clinical Study of a New Extended Wear Infusion Set Design. Presented at Advanced Technologies &amp; Treatments for Diabetes Conference, 19-22 February, 2020, Madrid, Spain (2020). Diabetes Technology &amp; Therapeutics.Feb 2020.A-1-A-250. https://doi.org/10.1089/dia.2020.2525.abstracts</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang JY, Shang T, Chattaraj S, et al. Advances in insulin pump infusion sets symposium report. J Diabetes Sci Technol. 2021;15:705-709.</Citation>
        </Reference>
        <Reference>
          <Citation>Buckingham, B. A., Brazg, R. L., Bailey, T. S., Kudva, Y. C., Garg, S. K., Grunberger, G., Thrasher, J., Cavale, A., Bhargaba, A., Horowitz, B., Kaiserman, K., Huang, S., Chen, V., Zhang, G., Chattaraj, S., Shin, J. &amp; Vigersky, R. 100-LB - infusion set survival and performance during the Medtronic extended-wear infusion set (EWIS) pivotal trial. Presented at: American Diabetes Association Virtual 81st Scientific Sessions; June 25-29, 2021; online (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Kastner, J. R., Eisler, G., Torjman, M. C., Khalf, A., Diaz, D., Dinesen, A. R., Loeum, C., Thakur, M. L., Strasma, P. &amp; Joseph, J. I. Novel kink-resistant insulin infusion set causes significantly less subcutaneous tissue inflammation compared with a straight Teflon insulin infusion set. Presented at Advanced Technologies &amp; Treatments for Diabetes Conference, 19-22 February, 2020, Madrid, Spain (2020). Diabetes Technology &amp; Therapeutics.Feb 2020.A-1-A-250. https://doi.org/10.1089/dia.2020.2525.abstracts</Citation>
        </Reference>
        <Reference>
          <Citation>Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593-1603.</Citation>
        </Reference>
        <Reference>
          <Citation>Gomez-Peralta F, Dunn T, Landuyt K, Xu Y, Merino-Torres JF. Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. BMJ Open Diabetes Res Care. 2020;8:e001052.</Citation>
        </Reference>
        <Reference>
          <Citation>Šoupal J, Petruželková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care. 2020;43:37-43.</Citation>
        </Reference>
        <Reference>
          <Citation>Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23:601-608.</Citation>
        </Reference>
        <Reference>
          <Citation>Kesserwan S, Mulka A, Sharafieh R, et al. Advancing continuous subcutaneous insulin infusion in vivo: new insights into tissue challenges. J Biomed Mater Res A. 2020;109:1065-1079. doi:10.1002/jbm.a.37097</Citation>
        </Reference>
        <Reference>
          <Citation>Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152:622-628.</Citation>
        </Reference>
        <Reference>
          <Citation>Pickup JC, Yemane N, Brackenridge A, Pender S. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther. 2014;16:145-149.</Citation>
        </Reference>
        <Reference>
          <Citation>van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin Glulisine compared to insulin Aspart and to insulin Lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13:607-614.</Citation>
        </Reference>
        <Reference>
          <Citation>Kovatchev B. Glycemic variability: risk factors, assessment, and control. J Diabetes Sci Technol. 2019;13:627-635. doi:10.1177/1932296819826111</Citation>
        </Reference>
        <Reference>
          <Citation>Pfützner A, Musholt PB, Malmgren-Hansen B, Nilsson NH, Forst T. Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste. J Diabetes Sci Technol. 2011;5:843-847.</Citation>
        </Reference>
        <Reference>
          <Citation>Heinemann L, Krisiunas E. Diabetes technology and waste: a complex problem piling up! J Diabetes Sci Technol. 2019;13:815-816.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
